Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.

Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace (2015) 1.98

Ablation of atrial fibrillation. Trends Cardiovasc Med (2014) 1.41

A Review of the Key Clinical Trials of 2014. Cardiol Ther (2015) 1.38

Cardioversion in Non-Valvular Atrial Fibrillation. Dtsch Arztebl Int (2015) 1.18

Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis. Clin Res Cardiol (2015) 0.91

Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study. PLoS One (2015) 0.84

Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation (2017) 0.82

Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial. Europace (2015) 0.82

Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities. Drugs (2015) 0.82

Factors in Deciding between Novel and Traditional Oral Anticoagulants to Prevent Embolism in Atrial Fibrillation Patients. Arq Bras Cardiol (2016) 0.79

Left atrial thrombus formation and resolution during dabigatran therapy: A Japanese Heart Rhythm Society report. J Arrhythm (2015) 0.78

Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation. Arrhythm Electrophysiol Rev (2015) 0.78

Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation. Vasc Health Risk Manag (2015) 0.77

Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon? Intern Emerg Med (2017) 0.76

Cardioversion Of Atrial Fibrillation And Oral Anticoagulation. J Atr Fibrillation (2015) 0.75

Controversy Surrounding ROCKET-AF: A Call for Transparency, But Should We Be Changing Practice? Arrhythm Electrophysiol Rev (2016) 0.75

Anticoagulant therapy: Rivaroxaban for patients with AF undergoing cardioversion. Nat Rev Cardiol (2014) 0.75

A Comparison Between NOACs and Warfarin on Time to Elective Cardioversion. J Atr Fibrillation (2016) 0.75

Non-vitamin K antagonist oral anticoagulants versus warfarin for cardioversion of atrial fibrillation in clinical practice: A single-center experience. J Arrhythm (2016) 0.75

Underuse of Oral Anticoagulants for Nonvalvular Atrial Fibrillation: Past, Present, and Future. Tex Heart Inst J (2016) 0.75

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. Core Evid (2015) 0.75

Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists. Eur J Med Res (2016) 0.75

Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation. Am J Cardiovasc Drugs (2015) 0.75

Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. Cardiol Res (2015) 0.75

Evaluating cardioversion outcomes for atrial fibrillation on novel oral anticoagulants versus warfarin: experience at a tertiary referral centre. Ir J Med Sci (2017) 0.75

Use of rivaroxaban in patients with stroke. Neurol Sci (2017) 0.75

2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm (2017) 0.75

Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion. Am Heart J (2014) 1.62

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vasc Health Risk Manag (2014) 0.91

Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial. Europace (2015) 0.82

Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. Intern Emerg Med (2016) 0.79

Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J (2015) 0.78

Outcomes associated with observation stays versus inpatient admissions for pulmonary embolism. J Thromb Thrombolysis (2016) 0.75

Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. Int J Clin Pract (2017) 0.75

Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxaban. Int J Cardiol (2016) 0.75